Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia...
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, underpriced on P/FCF.
Target Price
The average target price of KROS is 22 and suggests 102% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell